Meeting on Open Innovation in Rome on the 2nd
Promise to commercialize world and broaden joint R&D
![On the 2nd, a visiting group is taking a commemorative photo with officials in Angelini Pharma, Rome, Italy. (From third left) Cho Seong-jin, CEO of Cureverse, Paolo Di Georzo Angelini Ventures, CSO Rafale Kaminsky Angelini Pharma, Chairman of the Special R&D Zone Promotion Foundation, Lee Chang-joon, Chairman of the Basic Science Research Institute, and Park Ki-duk, Director of the Korea Institute of Science and Technology. [Photo = Special Zone Foundation]](https://wimg.mk.co.kr/news/cms/202603/03/news-p.v1.20260303.85c3eccff6284cfbb5df2a95c8470c65_P1.jpg)
The R&D Special Zone Promotion Foundation visited Italian pharmaceutical company Angelini Pharma on the 2nd and held an open innovation assembly to commercialize particular zone biotechnology and broaden joint R&D cooperation.
The go to was attended by the Brain Disease Research Group of the Korea Institute of Science and Technology, the Memory and Glioblast Research Group of the Institute of Basic Science, and Curebus, a company that develops new medicine for mind ailments. At a gathering attended by Angelini Pharma CEO Sergio Marulo di Condoyanni, they mentioned analysis and improvement methods within the central nervous system, the path of know-how introduction, and methods to broaden cooperation.
Angelini Pharma is a world pharmaceutical company primarily based in Italy that operates in additional than 20 nations, together with Europe and North America, specializing in the central nervous system (CNS).
Recently, a particular zone company and Angelini Pharma signed a big know-how switch contract one after one other. Curebus, a analysis institute within the Hongneung Kangso Special Zone, signed a 500 billion gained know-how switch contract with Angelini Pharma in 2024 primarily based on CV-01, a candidate for the remedy of neurodegenerative ailments, and is presently collectively selling medical improvement by the Special Zone Foundation’s Global Cluster R&BD Project’.
Subagen, a deep tech company within the Daedeok Special Zone bio sector, additionally signed a contract price 750 billion gained with Angelini Pharma in 2025 by the know-how switch of SVG105, a brand new drug candidate for refractory epilepsy.
“The innovative technology and research capabilities of special zone bio companies are very impressive,” stated CEO Di Condoyanni. “We look forward to continuously expanding opportunities for discovering promising pipelines and joint R&D through cooperation with the special zone foundation.”
“This visit is an opportunity to further expand cooperation with Angelini Pharma, which confirmed the competitiveness of the special zone biotechnology,” stated Chung Hee-kwon, chairman of the Special Zone Foundation. “We will further solidify the commercialization ecosystem where the special zone’s excellent technology is directly connected to the global market by upgrading the foundation’s global technology commercialization program and strengthening demand-based technology matching and support for companies to enter the market.”